Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.110 million which missed the analyst consensus estimate of $10.000 million by 88.90 percent.